ANDAORALTABLET
Approved
Jan 2003
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
3/8 — Basic
NABUMETONE (nabumetone) by Molecular Devices is cyclooxygenase inhibitors [moa]. First approved in 2003.
Drug data last refreshed 18h ago
Mechanism of Action
Cyclooxygenase Inhibitors
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Bioequivalence Study of Nabumetone 750 mg Tablets of Dr. Reddy's Under Fed Conditions
Started Mar 2006
30 enrolled
Healthy
Bioequivalence Study of Nabumetone 750 mg Tablets of Dr. Reddy's Under Fasting Conditions
Started Mar 2006
44 enrolled
Healthy
Company
Worked on NABUMETONE at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.